News
.jpeg)
Biotech start-up Immuneel Therapeutics announces India’s first Phase II patient trials for CAR-T cancer therapies alongside a USD 15 million Series A financing
INDIA – Immuneel Therapeutics (‘Immuneel’), India’s leading biotech start-up focused on creating access to Chimeric Antigen Receptor T cell therapy (CAR-T) and other cellular immunotherapies for the management and treatment of cancers, has begun patient dosing in a CAR-T trial named “IMAGINE”. This phase II trial is the first industry sponsored CAR-T trial in India and is now actively enrolling patients at Narayana Hrudayalaya, Bengaluru.
Avesthagen Limited enters into strategic alliance with Wipro; Launches breakthrough genetic testing portfolio for cancers, neurological and rare diseases
Avesthagen Limited, a biotechnology major that specializes in predictive, preventive and personalized healthcare through the convergence of food, pharma and population genetics, has entered into a four-year strategic alliance with Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, for making its genetic testing portfolio commercial. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.
Genomepatri Heritage, Mapmygenome’s DNA-based Ancestry Test Now Covers All of India
Genomepatri Heritage is Mapmygenome's DNA- based ancestry analysis, through which one can discover their ancestry roots. It is also one of our best-selling genomic tests. This heritage analysis now has comprehensive data on the ethnicity composition of every Indian state along with a global database.
Fighting Superbugs: How an Indian Avenger is building a life-saving weapon
Big pharma has little interest in antibiotics because there's not enough money in it, making Bugworks, with its R&D in India, among a handful of startups that is attempting the impossible
GARDP supports Bugworks in assessing safety of new antibiotic compound
Global Antibiotic Research and Development partnership (GARDp), a not-for-profit entity created by he WHO and DnDi, spearheading the fight against Antimicrobial Resistance (AMR), announces a collaboration with Bugworks via supporting the cardiac safety assessment studies of Bugworks' lead molecule BWC0977, currently going through Phase 1 studies in Adelaide Australia.
BioEconomy Conclave 2026
